Mortality within 28 days · people with acute respiratory infections
1 finding from 1 review
Number of participants in need of a hospital admission within 28 days · people with acute respiratory infections
1 finding from 1 review
Number of participants given an antibiotic prescription at index consultation  · people with acute respiratory infections
1 finding from 1 review
Number of participants given an antibiotic prescription within 28 days · people with acute respiratory infections
1 finding from 1 review
All‐cause mortality maximum · neonates and children with hospital‐acquired pneumonia
It is very uncertain whether cefepime changes all‐cause mortality Maximum compared with ceftazidime (very low certainty).
1 finding from 1 review
Health‐related quality of life Maximum · neonates and children with hospital‐acquired pneumonia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Mortality (pneumonia-associated) · neonates and children with hospital‐acquired pneumonia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Non‐serious adverse events Maximum · neonates and children with hospital‐acquired pneumonia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events maximum · neonates and children with hospital‐acquired pneumonia
It is very uncertain whether cefepime changes serious adverse events Maximum compared with ceftazidime (very low certainty).
1 finding from 1 review
Treatment failure Maximum · neonates and children with hospital‐acquired pneumonia
It is very uncertain whether cefepime changes treatment failure Maximum compared with ceftazidime (very low certainty).
1 finding from 1 review
Health‐related quality of life Maximum · neonates and children with hospital‐acquired pneumonia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Mortality (pneumonia-associated) · neonates and children with hospital‐acquired pneumonia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Non‐serious adverse events Maximum · neonates and children with hospital‐acquired pneumonia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
All‐cause mortality maximum · neonates and children with hospital‐acquired pneumonia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events maximum · neonates and children with hospital‐acquired pneumonia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Treatment failure Maximum · neonates and children with hospital‐acquired pneumonia
It is very uncertain whether linezolid changes treatment failure Maximum compared with vancomycin (very low certainty).
1 finding from 1 review
Intervention not reported
Death · children and adults with acute bacterial meningitis
The intervention showed no clear difference in death (moderate certainty).
1 finding from 1 review
Intervention not reported
Neurological disability · children and adults with acute bacterial meningitis
The intervention showed no clear difference in neurological disability (low certainty).
1 finding from 1 review
Intervention not reported
Seizures · children and adults with acute bacterial meningitis
The intervention showed no clear difference in seizures (low certainty).
1 finding from 1 review
Intervention not reported
Hearing loss · children and adults with acute bacterial meningitis
The intervention probably leads to lower hearing loss (moderate certainty).
1 finding from 1 review